Bedford, Mass.-based insulin management devices maker Insulet (NSDQ:PODD) landed an FDA nod for its next-generation OmniPod insulin pump.
Insulet
Insulet gains after hours on Q3 results
Insulet (NSDQ:PODD) shares gained after the market’s close today after the medical device company reported strong sales growth and lower losses for the 3rd quarter.
Bedford, Mass.-based Insulet reported losses of $12.4 million, or 26¢ per share, on sales of $54.8 million during the 3 months ended Sept. 30, reducing losses by some 8.4%.
CardioInsight names Patrick Wethington new CEO | Personnel Moves
Diabetes: Medtronic sues Insulet over OmniPod device
Teleflex expands catheter OEM business | Wall Street Beat
Hacking Healthcare: Are insulin pumps more susceptible to attack?
Insulin pumps are designed to be convenient and easy to use, but those features may make them more vulnerable to a hacker, a new report says.
Diabetes: Insulet gains on Q2 results
iRhythm appoints Kevin King president & CEO | Personnel Moves
Greatbatch proposes to mostly exit Switzerland for Indiana, Mexico | Wall Street Beat
Greatbatch (NYSE:GB) said it wants to largely shutter a pair of plants in Switzerland and relocate their operations to Ft. Wayne, Ind., and Tijuana, Mexico.
Medical Device Tax: SCOTUS ruling on healthcare reform a long-term boon for medical device companies
The U.S. Supreme Court’s decision to uphold the healthcare reform law – and therefore the medical device tax – could bode well for medical device companies over the long term, Wall Street analysts say.
Companies have already baked the impact of the 2.3% revenue tax into their assumptions, as have most med-tech investors, the analysts say. That likely means a short-term hit on The Street, as the upside of repeal evaporated this morning, but longer-term growth as 30 million to 40 million new patients gain health insurance.